Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 14/20 | 0.66 |
| ▸ | MAPT | P10636 | 14/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.63 |
| ▸ | DCTPP1 | Q9H773 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2389697 | 0.88 | MAPT (0.66) | ALDH1A1MAPTLMNAMAPK1NPSR1 | |
| SCHEMBL16752999 | 0.88 | MAPT (0.59) | ALDH1A1MAPTLMNAMAPK1NPSR1 | |
| SCHEMBL7937307 | 0.87 | ALDH1A1 (0.65) | ALDH1A1MAPTLMNAMAPK1NPSR1 | |
| SCHEMBL1846909 | 0.86 | DCTPP1 (0.74) | ALDH1A1MAPTLMNAMAPK1NPSR1 | |
| SCHEMBL1840936 | 0.86 | ALDH1A1 (0.64) | ALDH1A1MAPTLMNAMAPK1NPSR1 | |
| SCHEMBL12497325 | 0.85 | MAPT (0.67) | ALDH1A1MAPTLMNAMAPK1NPSR1 | |
| SCHEMBL1846449 | 0.85 | DCTPP1 (0.81) | ALDH1A1MAPTLMNAMAPK1NPSR1 | |
| SCHEMBL1843709 | 0.85 | MAPT (0.57) | ALDH1A1MAPTLMNAMAPK1NPSR1 | |
| SCHEMBL1843205 | 0.84 | MAPT (0.82) | ALDH1A1MAPTLMNAMAPK1NPSR1 | |
| SCHEMBL12497103 | 0.84 | DCTPP1 (0.69) | ALDH1A1MAPTLMNAMAPK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2320897-A1 | COMPOSITIONS AND METHODS OF TREATING AMYLOID DISEASE | Treventis Corporation (US) | 2011-05-18 | — | — | EP | claimed |
| WO-2010025375-A1 | COMPOSITIONS AND METHODS OF TREATING AMYLOID DISEASE | TREVENTIS CORPORATION (US) | 2010-03-04 | — | — | WO | claimed |
| US-11568956-B2 | Methods for identifying inhibitors of amyloid protein aggregation | TREVENTIS CORPORATION (US) | 2023-01-31 | — | — | US | disclosed |
| US-11568956-B2 | Methods for identifying inhibitors of amyloid protein aggregation | TREVENTIS CORPORATION (US) | 2023-01-31 | — | — | US | disclosed |
| EP-3110812-B1 | ANTI-AMYLOID COMPOUNDS CONTAINING BENZOFURAZAN | TREVENTIS CORP (US) | 2019-04-10 | — | — | EP | disclosed |
| US-20190050526-A1 | METHODS FOR IDENTIFYING INHIBITORS OF AMYLOID PROTEIN AGGREGATION | TREVENTIS CORPORATION (US) | 2019-02-14 | — | — | US | disclosed |
| US-20190050526-A1 | METHODS FOR IDENTIFYING INHIBITORS OF AMYLOID PROTEIN AGGREGATION | TREVENTIS CORPORATION (US) | 2019-02-14 | — | — | US | disclosed |
| US-9938249-B2 | Anti-amyloid compounds containing benzofurazan | TREVENTIS CORPORATION (US) | 2018-04-10 | — | — | US | disclosed |
| US-9938249-B2 | Anti-amyloid compounds containing benzofurazan | TREVENTIS CORPORATION (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170174641-A1 | ANTI-AMYLOID COMPOUNDS CONTAINING BENZOFURAZAN | TREVENTIS CORPORATION (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170174641-A1 | ANTI-AMYLOID COMPOUNDS CONTAINING BENZOFURAZAN | TREVENTIS CORPORATION (US) | 2017-06-22 | — | — | US | disclosed |
| EP-2320897-B1 | COMPOSITIONS AND METHODS OF TREATING AMYLOID DISEASE | TREVENTIS CORP (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8420640-B2 | Methods of treating amyloid disease using analogs of 1-(4-nitrophenyl) piperazine | TREVENTIS CORPORATION (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420640-B2 | Methods of treating amyloid disease using analogs of 1-(4-nitrophenyl) piperazine | TREVENTIS CORPORATION (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420640-B2 | Methods of treating amyloid disease using analogs of 1-(4-nitrophenyl) piperazine | TREVENTIS CORPORATION (US) | 2013-04-16 | — | — | US | disclosed |
| US-20110218200-A1 | METHODS OF TREATING AMYLOID DISEASE USING ANALOGS OF 1-(4-NITROPHENYL) PIPERAZINE | TREVENTIS CORPORATION | 2011-09-08 | — | — | US | disclosed |
| US-20110218200-A1 | METHODS OF TREATING AMYLOID DISEASE USING ANALOGS OF 1-(4-NITROPHENYL) PIPERAZINE | TREVENTIS CORPORATION | 2011-09-08 | — | — | US | disclosed |
| EP-2320897-A1 | COMPOSITIONS AND METHODS OF TREATING AMYLOID DISEASE | Treventis Corporation (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010025375-A1 | COMPOSITIONS AND METHODS OF TREATING AMYLOID DISEASE | TREVENTIS CORPORATION (US) | 2010-03-04 | — | — | WO | disclosed |
| WO-2010025375-A1 | COMPOSITIONS AND METHODS OF TREATING AMYLOID DISEASE | TREVENTIS CORPORATION (US) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218200-A1 | METHODS OF TREATING AMYLOID DISEASE USING ANALOGS OF 1-(4-NITROPHENYL) PIPERAZINE | PSEN1, PSEN2, APP | ALDH1A1 1948/4885MAPT 10/4885LMNA 528/4885 |
| US-20170174641-A1 | ANTI-AMYLOID COMPOUNDS CONTAINING BENZOFURAZAN | PRNP, PSEN1, APP | ALDH1A1 1441/4885MAPT 14/4885LMNA 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.